Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Sutent Prescribers for RCC: Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
February 8, 2008
Diabetes Mellitus Trial: Disclaimer: I am not a diabetes expert but I have been a physician x 39 years....
Analysis of: Diabetes Study Partially Halted After Deaths | www.nytimes.com
Author: GLG Expert Contributor
".... a major federal study of more than 10,000 middle-aged and older people with Type 2 diabetes (DM) has found that lowering blood sugar actually increased their risk of death, researchers reported Wednesday."
Donald FlemingFebruary 6, 2008
Sutent and NSCLca
Analysis of: Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Sutent is demonstrating some activity in Lung cancer Sutent is unique in this regard versus other TKIs ? I would focus on the FELT for obvious reasons
Donald FlemingFebruary 6, 2008
Hematide ; Just another ESA?
Analysis of: Takeda Doses First Patient in A U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia | www.pipelinereview.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Hematde is a new ESA with potential benefit over older ESAs hematide may look especially god coming off some of the recent FDA concerns abiut ESAs
Donald FlemingFebruary 6, 2008
The US not quite ready to throw in the iv pole
Analysis of: GlaxoSmithKline receives EMEA positive opinion for the approval of Hycamtin® (topotecan) hard capsules for the treatment of relapsed small cell lung cancer | www.pipelinereview.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
New oral agents to replae previous iv meds will not likelty succeed in near future in US patient's are less compliant with oral meds, even for cancer
February 5, 2008
GlaxoSmithKline (GSK) oral Topotecan: Impact? Use?
Analysis of: GlaxoSmithKline receives EMEA positive opinion for the approval of Hycamtin® (topotecan) hard capsules for the treatment of relapsed small cell lung cancer | www.pipelinereview.com
Author: GLG Expert Contributor
An oral version of Topotecan that can be used 2nd line in SCLCA. Impact?
February 4, 2008
Velcade: 1st line indication probable, but is it really better and easier??
Analysis of: FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma | www.pipelinereview.com
Author: GLG Expert Contributor
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) is pressing for approval of Velcade in a first line rather than second line + setting. This would definitely increase sales
February 1, 2008
Lung Cancer: Make way for Sutent (Pfizer)
Analysis of: Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
Preliminarily appears to be effective in Non Small Cell Carcinoma of the Lung (NSCLCA). Overall response rates are comparable to standard second line agent efficacy, and its ORAL.
January 31, 2008
Statins: I Knew It, I Knew It, I Knew It......
Analysis of: Great Drug, but Does It Prolong Life? | www.nytimes.com
Author: GLG Expert Contributor
For people without cardiovascular disease or > 70 there is no benefit to statins!!!!
January 30, 2008
Panzem and Avastin Active in Carcinoid Tumors? I'm not so sure....
Analysis of: EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study | www.pipelinereview.com
Author: GLG Expert Contributor
Panzem is an oral formulation of 2-methoxyestradiol with multiple anti-tumor actions. These include tubulin disruption to halt mitosis (cell division), apoptosis stimulation and, similarly to Avastin (bevacizumab), angiogenesis inhibition.      87% of patients had stable disease...
January 29, 2008
Roche Holding AG : Avastin in the EU receives approval for wider applicability
Analysis of: Roche's Avastin Cleared For Wider Use in the EU | online.wsj.com
Author: GLG Expert Contributor
Avastin was approved for wider use in the EU with multiple chem agents including Roche's Xeloda (Can you say synergy?)

Previous Page : 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next171 to 180 of 506

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203